Incyte (NASDAQ:INCY) announced that its novel monoclonal antibody, INCA033989, has shown safety and efficacy in treating essential thrombocythemia (ET), according to new data presented at the European Hematology Association (EHA) congress in Milan. The late-breaking oral presentation, held on June 15, detailed the impact of INCA033989’s mechanism of action on mutCALR-driven ET, a myeloproliferative neoplasm (MPN).
The company believes this first-in-class, mutCALR-directed therapy has the potential to modify the disease and transform treatment for patients with MPNs like ET. Incyte’s President and Head of Research and Development, Pablo J. Cagnoni, M.D., expressed optimism about the data’s demonstration of INCA033989’s transformative potential.
Incyte’s hematology/oncology portfolio featured prominently at the EHA congress, with several abstracts accepted for presentation. These included findings on INCA035784, a T cell redirecting antibody for patients with MPNs carrying different types of calreticulin mutations, and clinical outcomes associated with the use of ruxolitinib and anemia supporting medications in myelofibrosis treatment.
The company also highlighted data on tafasitamab in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma, and various studies on axatilimab for chronic graft-versus-host disease. Other presentations covered the BET protein inhibitor INCB057643’s role in myeloproliferative neoplasms and the impact of ponatinib treatment on pregnancy outcomes.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.